REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
REGENXBIO Inc. reported that its Chief Financial Officer, Mitchell Chan, received new equity awards on January 6, 2026. He was granted 73,749 shares of common stock underlying a time-based restricted stock unit (RSU) award at a grant price of $0.00 per share. These RSUs vest in four equal installments of 25% each on January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030, as long as he continues providing service to the company.
Chan also received 39,650 stock options with an exercise price of $14.18 per share, expiring on January 6, 2036. For this option grant, 25% of the shares vest after 12 months of continuous service, with the remaining 75% vesting in equal monthly installments over the 36 months following January 6, 2027. After these reported grants, he directly beneficially owned 127,717 shares of common stock and 39,650 stock options.
REGENXBIO Inc. Chief Strategy & Legal Officer Patrick J. Christmas reported a tax-related share withholding transaction. On January 2, 2026, 9,793 shares of REGENXBIO common stock were withheld at a price of $14.4 per share to cover taxes due upon the vesting of previously granted restricted stock units.
These restricted stock units were originally granted on January 3, 2022, January 3, 2023 and January 2, 2024. After this withholding, Christmas beneficially owned 141,618 shares of REGENXBIO common stock, held directly.
REGENXBIO Inc. filed a shelf registration statement allowing it to offer and sell up to $300,000,000 of securities over time. The mix may include common stock, preferred stock, warrants, debt securities, rights and units, in one or more offerings, with final terms set in future prospectus supplements. Any securities can be sold directly, or through underwriters, dealers or agents.
REGENXBIO, a gene therapy-focused biotechnology company, plans to use net proceeds for general corporate purposes, including financing clinical trials, capital expenditures, working capital, pipeline development, expanding commercial capabilities, general and administrative expenses, potential debt repayment and possible acquisitions or investments. Its common stock trades on the Nasdaq Global Select Market under the symbol RGNX and closed at $13.45 on November 25, 2025. As of September 30, 2025, 50,618,692 shares of common stock were outstanding.
REGENXBIO Inc. (RGNX) furnished quarterly results. The company submitted an 8‑K announcing it issued a press release covering results of operations and financial condition for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference therein.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act. REGENXBIO’s common stock trades on the Nasdaq Global Select Market under the symbol RGNX.
REGENXBIO Inc. reported Q3 2025 results. Total revenue was $29.7 million, driven by $23.6 million of license and royalty revenue and $6.1 million of service revenue. For the nine months, revenue reached $140.1 million.
The company posted a Q3 net loss of $61.9 million and a basic and diluted net loss per share of $1.20. Interest expense rose to $13.2 million in the quarter, reflecting royalty financing activity. Operating expenses were $82.1 million in Q3, led by $56.1 million in research and development and $20.3 million in general and administrative costs.
Cash, cash equivalents and marketable securities totaled $302.0 million as of September 30, 2025. Royalty monetization liabilities increased to $191.6 million, including a new 2025 Royalty Bond initially funded with $150.0 million (net proceeds $144.5 million). Deferred revenue rose to $34.4 million current and non-current combined, aligned with recent collaboration activity and the new presentation separating service revenue. Shares outstanding were 50,623,086 as of October 31, 2025.
Simpson Curran, who is listed as both Chief Executive Officer and a Director of REGENXBIO Inc. (RGNX), reported an open-market sale of company common stock under a pre-existing trading plan. On 10/09/2025 the reporting person disposed of 20,811 shares at a weighted average price of $12.62 per share, with the filing noting the sale was effected pursuant to a Rule 10b5-1 trading plan and executed in multiple trades at prices ranging from $12.50 to $12.84.
Following this reported transaction the reporting person beneficially owned 216,162 shares. The Form 4 was signed via attorney-in-fact on 10/10/2025.
REGENXBIO, Inc. (RGNX) filed a Form 144 notifying the proposed sale of 20,811 common shares with an aggregate market value of $254,310.42, scheduled for 10/09/2025 and to be executed on the NASDAQ. The shares were acquired as Restricted Stock Units on 01/01/2025, and the filer indicates the securities were granted by the issuer.
The filing discloses recent Rule 10b5-1 sales by the same person: 7,624 shares sold on 09/29/2025 for $76,434.41 and 7,734 shares sold on 09/10/2025 for $77,530.26. Outstanding shares are listed as 50,514,216, making the proposed sale a small fraction of total outstanding equity.
Simpson Curran, serving as Chief Executive Officer and a director of REGENXBIO Inc. (RGNX), reported a sale of 7,624 shares of the issuer's common stock on 09/29/2025. The sale was effected under a Rule 10b5-1 trading plan and executed in multiple trades at prices ranging from $10.00 to $10.08, with a weighted average sale price of $10.03. Following the reported transaction, the reporting person beneficially owned 236,973 shares, held directly. The Form 4 was signed by an attorney-in-fact, Patrick J. Christmas, on 10/01/2025. No derivative transactions or other securities classes were reported in this filing.
REGENXBIO Inc. (RGNX) filed a Form 144 notifying the proposed sale of 15,358 shares of its common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $151,890.62 and an approximate planned sale date of 09/10/2025 on NASDAQ.
The shares were acquired as Restricted Stock Units from the issuer on 01/01/2023 and total outstanding shares are reported as 50,514,216, making the planned sale approximately 0.03% of outstanding stock. The filing affirms the signer does not possess undisclosed material adverse information and indicates no securities were sold in the past three months by the reporting person.
Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (RGNX), reported a non-derivative transaction dated 09/01/2025 in which 234 shares of common stock were disposed at a price of $8.93 per share. After the transaction he beneficially owned 17,585 shares directly. The filing states the 234 shares were withheld to pay taxes upon the vesting of restricted stock units originally granted on September 1, 2022, with the withholding amount calculated using the issuer's closing stock price on August 29, 2025. The form was signed via attorney-in-fact on 09/03/2025.